The cell-of-origin of high grade serous ovarian carcinoma (HGSOC) remains controversial, with fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE) each suggested as candidates. Here, by using genetically engineered mouse models and novel organoid systems, we assessed the tumor-forming capacity and properties of FTE and OSE harboring the same oncogenic abnormalities. Combined RB family inactivation (via T121 expression) and Tp53 mutation in Pax8+ FTE caused transformation to Serous Tubal Intraepithelial Carcinoma (STIC), which rapidly metastasized to the ovarian surface. This mouse model was recapitulated by FTE organoids, which, upon orthotopic injection, generated widely metastatic HGSOC. The same genetic lesions in Lgr5+ OSE cells or organoids also caused metastatic HGSOC, although with longer latency and lower penetrance. Comparative transcriptome analysis was consistent with different human HGSOCs arising from FTE and OSE. Furthermore, FTE-and OSE-derived organoids showed differential sensitivity to HGSOC chemotherapeutics. Our results comport with a dualistic origin for HGSOC and suggest the cell-of-origin could influence therapeutic response.
INTRODUCTION
High-grade serous ovarian cancer (HGSOC) is the most common and deadly ovarian epithelial cancer, causing ~70% of ovarian cancer deaths (1) . Although HGSOC typically presents as a large ovarian mass accompanied by widespread peritoneal metastasis, its cell-of-origin remains controversial (2) (3) (4) (5) . Historically, as its name implies, HGSOC was thought to arise from the ovarian surface epithelium (OSE) or, more specifically, from cortical inclusion cysts, invaginations that result from normal ovulatory "wounds." "Trapped" OSE within these cysts were believed to undergo Mullerian metaplasia and accumulate causal mutations (5) (6) (7) . Cortical inclusion cysts with columnar (Mullerian) epithelia and focal p53 immunoreactivity, but not frank carcinoma, have been reported, although such lesions are relatively rare (8, 9) . More recently, attention has turned to the fallopian tube epithelium (FTE) as the cell of origin for HGSOC. Initial studies revealed lesions termed Serous Tubular Intraepithelial Carcinomas (STICs) in the fallopian tube fimbria of women with BRCA1/2 mutations undergoing riskreducing salpingoophorectomy (10) (11) (12) . Subsequently, STICs were reported in up to 60% of sporadic HGSOC patients (13) (14) (15) .
Molecular analyses strongly support a fallopian tube (FT) origin of most cases of HGSOC. Essentially all HGSOCs have TP53 somatic mutations, and STICs, primary tumors and HGSOC metastases have the same TP53 mutation, implying a shared origin (17) (18) (19) (20) . More comprehensive genomic characterization (e.g., exome sequencing, copy number analyses, targeted amplicon deep sequencing and gene expression profiling) has shown that, in most cases, ovarian masses and distant metastases have the same "truncal" lesions as STICs, but also possess additional, often sub-clonal, genomic abnormalities, suggesting that STICs are precursor lesions (13, 21) . Consistent with these findings, the transcriptome of most HGSOCs more closely resembles that of normal FTE than to OSE; nevertheless, up to 12% of HGSOCs show greater transcriptional similarity to OSE (22, 23) . Furthermore, some genomic studies have found that HGSOC can metastasize to the FT and mimic STICs (24, 25) , consistent with a non-FTE origin. In addition, FTs can harbor metastases that mimic STICs but arise from other sites (e.g., uterine serous carcinoma) (25) (26) (27) (28) . The Mullerian features of HGSOC have been cited as evidence of a FT origin, as FT is a Mullerian-derived structure. However, OSE and FTE share an even earlier embryonic progenitor (6, 29, 30) , and inappropriate expression of HOX family members can confer Mullerian-like features in mouse models (31) .
Mouse modeling has also failed to definitively define the cell-of-origin for HGSOC. Lineage tracing identified a stem cell niche in the mouse ovarian hilum containing Lgr5+ cells that can give rise to the entire OSE, and it was suggested that these cells were the target of transformation in HGSOC pathogenesis (32) . HGSOC-like tumors have been generated by injecting adenovirus expressing Cre recombinase (Ad-Cre) into the ovarian bursae of mice bearing conditional alleles of tumor suppressor genes and/or oncogenes, including Myc;Tp53;Brca1 (33), Pten;Pik3ca (34), Tp53;Rb1 (35) , or TgK18GT 121 (N-terminal 121 amino acids of SV40 T antigen (T121) under the control of the keratin 18 promoter) and flTp53, + flBrca1 (36) . These reports concluded that HGSOC arises from OSE, but they did not exclude the possibility that FTE cells also were infected by Ad-Cre. Conversely, a mouse model with Pten deletion, Tp53 deletion or mutation, and Brca1/2 deletion driven by the Pax8 promoter, which is expressed selectively in FTE secretory cells (not in OSE) develops STIC-like lesions and eventually, widely metastatic HGSOC (37) . Similar results were seen with in mice that express SV40 large T-antigen (TAg) (38) or with simultaneous mutation of Brca1, Tp53, Rb1 and Nf1 in Ovgp1-expressing secretory FTE (39) .
In other neoplasms, the cell-of-origin can contribute to inter-tumor heterogeneity and distinct tumor biology (40) (41) (42) . Therefore, we used lineage-specific Cre recombinase (Cre) lines, combined with FTE-and OSE-derived organoids, to ask whether introducing the same genetic defects into FTE or OSE results in HGSOC, and if so, whether the resultant tumors have similar properties.
RESULTS

Perturbing Tp53 and the RB family in Pax8+ cells cause STIC and metastasis
TgK18GT121 (hereafter, "T121") mice harbor a bacterial artificial chromosome (BAC) containing a Creconditional loxP-GFP-stop-loxP (LSL) T121 cassette inserted into the mouse cytokeratin (CK) 18 gene. Inducing expression of T121 (which inactivates all RB family members) by bursal injection of Ad-Cre, when combined with Tp53 deletion or heterozygotic Tp53 R172H expression, results in HGSOC at a frequency of 70-90% (36) . These findings were interpreted as showing that OSE gives rise to HGSOC. However, Ad-Cre injection into mice with a Cre-inducible lacZ allele (Rosa26-lacZ) resulted in mosaic LacZ staining in FTE in addition to the expected strong OSE staining ( Supplementary Fig. S1 ), making the actual cell-of-origin in this model unclear. We therefore investigated the consequences of introducing the same ovarian cancer-associated genetic abnormalities into either FTE or OSE alone.
To this end, we generated T121;Tp53 R172H mice co-expressing appropriate lineage-specific Cre constructs.
Pax8rtTA mice reportedly enable doxycycline (Dox)-inducible gene expression in secretory FTE (37) . To confirm the lineage fidelity of this line, we generated Pax8rtTA;TetOCre:Rosa26-tdTomato reporter mice and Pax8rtTA;TetOCre:Rosa26-Lacz reporter mice ( Fig. 1A, Supplementary Figure 2 ). Following Dox administration (0.2 mg/ml in drinking water ad libitum) for 1 week, histologic analysis revealed strong β-gal reactivity in the FTE, but no staining in the ovary, including the OSE (Fig. 1B ). We also generated Pax8rtTA;TetOcre;Rosa26-tdTomato mice and exposed them to Dox for 2 days, followed by a "chase" in Dox-free water. At Day 2, Tomato+ cells colocalized with PAX8+ secretory FTE cells, as expected ( Supplementary Fig. 2A ). However, after 2 months of Doxfree "chase", secretory cells (PAX8+) and ciliated cells (which stain positive for acetylated α-tubulin) both were Tomato+ ( Supplementary Fig. S2B ). These data confirm that PAX8+ cells give rise to ciliated cells in vivo, consistent with a recent study (43) .
Having confirmed the selective expression of Pax8rtTA in FTE, we generated Pax8rtTA;TetOcre;Tp53 R172H/fl (hereafter, "PTP mice"), Pax8rtTA;TetOcre;T121 mice (hereafter, "PTT mice"), which direct inducible expression of T121 alone in Pax8+ cells, and Pax8rtTA;TetOcre;Tp53 R172H/fl ;T121 mice (hereafter, "PTPT mice"), which enable Dox-dependent expression of T121 and deletion of one Tp53 allele on a background of Tp53 R172H heterozygosity. As noted above, T121 mice contain a GFP reporter embedded within their LSL cassette (Fig. 1C ), which allows deletion efficiency to be monitored by absence of GFP. As expected, in the absence of Dox, GFP was detected diffusely in FTE, which exhibited very low levels of proliferation, as shown by Ki67 staining. Following Dox administration, the newly generated GFP-cells showed substantial Ki67 positivity, indicating that T121 evokes FTE proliferation ( Fig. 1D ). Within 1 month, FTE in Dox-activated PTPT mice showed clear evidence of transformation, with characteristic features of STIC, including secretory cell proliferation, loss of polarity, cellular atypia, and serous histology ( Fig. 1E and F). As early as 1 month post-Dox, metastases were detected on the ovarian surface ( Fig. 1G , compare boxed regions). Notably, 5/9 PTT mice underwent similar FTE transformation, suggesting that RB family inactivation alone can promote STIC. This finding is consistent with a previous study in which expressing SV40 large T antigen under control of the Ovgp-1 promoter resulted in STIC (38) . We did not detect STIC in PTP mice (0/9), but combining Tp53 perturbation with T121 expression significantly increased FTE transformation (from 55% to 100%) and metastasis (from 0 to 88%) to the ovary ( Fig.  1F and H). Immunohistochemical analysis (IHC) showed HGSOC-related features, including TP53 accumulation, proliferation and PAX8 expression in the primary lesion and the ovarian metastases of PTPT mice ( Fig. 1I and J).
Unexpectedly, PTT and PTPT mice died within 2 months ( Supplementary Fig. S3A ), but their demise was not due to peritoneal masses/obstruction, as would be expected with lethal HGSOC. Instead, these mice had markedly enlarged thymi, which led to breathing difficulties and ultimately, respiratory arrest ( Supplementary Fig.  S3B ). Combined Rb/p130 deletion/p107 heterozygosity causes a similar phenotype (44) , and surprisingly, reanalysis of Pax8rTtA;TetO-Cre; Rosa 26-tdTomato mice showed that TetO-Cre is active in thymic epithelial cells (although not in FTE) even in the absence of Dox ( Supplementary Fig. S3C ). This unanticipated "leakiness" of TetO-Cre in the thymic epithelium precluded us from asking if Pax8-driven T121 expression/Tp53 perturbation leads to widespread metastasis, although the early ovarian studding and our organoid studies (see below) make this highly likely.
FTE organoids recapitulate fallopian tube differentiation and transformation in vitro
Organoids initiated from adult stem cells can often be propagated long-term and are useful for cancer modeling (45, 46) . Culture conditions for human FTE organoids have been established (47) , but OSE organoids have not been reported, nor have human or mouse organoids been used to model HGSOC. We developed serumfree defined media that allow mouse FTE and OSE (see below) organoids to be passaged indefinitely (>30 passages) in Matrigel-based media, cryopreserved, and re-established in culture (see Methods). By 48hr after seeding FACSpurified EPCAM-/CD45-cells into such media, small (1-5 µm in diameter), round, cystic spheres appeared (EPCAM+CD45-), and they expanded rapidly to form large (100-1000 µm in diameter) hollow cysts. After 10 days, epithelial invagination resulted in mucosal folds, morphologically recapitulating FT architecture ( Fig. 2A ). Organoids cultured longer than 7 days contained secretory and ciliated cells, like their tissue of origin ( Fig. 2B ).
To evaluate the utility of this system for modeling HGSOC, we established organoid cultures from FTE of wild type, PTP, PTT, and PTPT mice. Dox-treated PTT and PTPT organoids activated Cre expression, as indicated by loss of GFP after 3 passages ( Fig. 2C and data not shown). Dox-treated (but not control) PTPT organoids exhibited frank dysplasia, TP53 accumulation, and staining for gH2AX, a marker of DNA damage ( Fig. 2D ). Consistent with our GEMM results ( Fig. 1 ), PTT and PTPT organoids proliferated more rapidly and were larger than controls ( Fig. 2E and F, Supplementary Fig. S4A and B ). By contrast, organoid-forming efficiency was not increased in mutants, suggesting that Tp53 mutation and/or RB family inactivation did not affect FTE self-renewal, as least under our culture conditions ( Supplementary Fig. S4C ). STIC and HGSOC typically are PAX8+ (although staining can be mosaic), and they do not express ciliated cell markers (48) . Similarly, ciliated cells were undetectable in PTT or PTPT organoids, suggesting that the RB family inactivation restricts FTE differentiation to the secretory lineage ( Fig. 2G and H). Tp53 R172H/mutation did not impair differentiation, but it enhanced invasive capability ( Fig.  2I and J). Thus, FTE organoids can be used to deconstruct various aspects of the malignant phenotype and attribute each to specific genetic defects.
FTE-derived organoids can give rise to HGSOC
We previously found that primary human HGSOC cells implanted into the mouse mammary fat pad (MFP) recapitulate HGSOC histomorphology, inter-and intra-tumor heterogeneity, and patient drug response (49, 50) . Therefore, as an initial test of their tumor-forming capacity, we injected wild type and mutant organoids into the MFPs of nu/nu mice ( Fig. 3A) . Wild type and Tp53 R172H/organoids formed glandular structures composed of simple cuboidal cells that persisted for at least 4 weeks, but these disappeared (n=0/8 for wild type, n=0/9 for PTP organoids) by 2 months (Fig. 3B-D) . By contrast, PTPT organoids formed easily palpable (>2mm) masses of high grade, poorly differentiated adenocarcinoma with prominent cellular/nuclear pleomorphism and frequent mitoses ( Fig. 3D ). PTT organoids also gave rise to HGSOC in 3 out of 8 mice, but consistent with our finding that biallelic Tp53 perturbation is associated with disease progression ( Fig. 1F and H) , PTPT organoids were more tumorigenic (7 out of 8 mice, Fig. 3B ). The ovary is thought to provide trophic signals that enable HGSOC growth and metastasis (51), so we also assessed tumorigenicity of organoids injected into the ovarian fat pad. PTT and PTPT organoids both gave rise to primary tumors, but within 3 months, 5/7 mice injected with PTPT organoids developed ascites, sometimes hemorrhagic, with widespread peritoneal studding similar to the human disease. By contrast, 0/7 lines of PTT-derived organoids showed evident metastasis at 9 months post-injection ( Fig. 3E and F). Metastases expressed HGSOC markers, including PAX8, p53, Ki67, γH2AX, Stathmin1 and p16 ( Fig. 3G ). Hence, our FTE organoid system recapitulates HGSOC biology morphologically and molecularly.
OSE also can give rise to HGSOC
Ad-Cre injection into the ovarian bursa of Tp53 R172H/fl ;T121 mice results in HGSOC (36), but as shown above, FTE cells also are infected under these conditions. As an initial test of whether OSE itself could serve as the HGSOC cell-of-origin, we performed salpingectomies 3 days after Ad-Cre injection into Tp53 R172H/fl ;T121 mice ( Supplementary Fig. S5A ). Gross inspection and histology of the ovaries of injected mice confirmed that the FT had been removed ( Supplementary Fig. S5B ). Nevertheless, when mice were examined 3 months later, the OSE showed abnormal morphology and hyperproliferation ( Supplementary Fig. S5C ), which prompted us to more carefully evaluate OSE as a potential cell-of-origin for HGSOC.
Lgr5+ embryonic and neonatal populations establish the OSE lineage and the fimbrial FTE (52) . In adult mice, however, Lgr5 expression is concentrated in the ovarian hilum, together with the stem cell markers CD133 and ALDH, and lineage-tracing using Lgr5Cre ERT2 mice showed that Lgr5+ cells can repopulate the entire OSE (32) . To confirm the lineage fidelity of this Cre line, and in particular, to assess its expression in adult FTE, we generated Lgr5Cre ERT2 ;Rosa26-tdTomato reporter mice. On Day 2 after administration of a single dose of 4-OHT (to induce CRE activity), there were sparse Tomato+ cells in OSE. By 4 months, though, these cells had expanded and populated a significant fraction of OSE. By contrast, there was no FTE expression at either time ( Fig. 4A and B).
We next generated Lgr5-Cre; Tp53 R172H/fl ;T121 (LPT) mice, and compared them with Lgr5-Cre; Tp53 R172H/fl (LP) and Lgr5-Cre;T121 (LT) mice, respectively ( Fig. 4C ). All mice received a single intraperitoneal dose of 4-OHT. As expected, LP mice (n=0/10) did not develop tumors, and only 1 out of 12 LT mice showed an obvious ovarian mass by 18 months after 4-OHT treatment. By contrast, all (11/11) LPT mice had large, palpable, abdominal masses by 11 months post-4-OHT injection ( Fig. 4D and E). Gross inspection revealed markedly enlarged, hemorrhagic ovaries, with 16% (n=2/11) developing multifocal peritoneal carcinomatosis and ascites ( Fig.  4D and F). Histology and IHC revealed poorly differentiated adenocarcinoma with papillary and micropapillary/filigree morphology ( Fig. 4G ), resembling human HGSOC. Notably, however, these tumors showed little PAX8 staining.
As an additional test of whether Lgr5+ OSE cells directly evoke HGSOC transformation, we generated compound LPT;Rosa 26-tdTomato mice ( Supplementary Fig. 6A ), administered a single dose of 4-OHT, and "chased" for 3, 6, or 9 months ( Supplementary Fig. 6B ). By 3 months following CRE activation, neoplasia had developed from Lgr5+ cells ( Supplementary Fig. 6C ). These lesions expanded, and at 6 months, >50% of the ovarian surface was covered by malignant, Tomato+ cells, whereas at 9 months, the surface was almost entirely overrun ( Supplementary Fig. 6C -F). Histologic examination again showed multi-villus neoplasia ( Supplementary  Fig. 6D and G), and IHC revealed highly proliferative tumors expressing HGSOC markers, including Wilms' tumor 1 (WT1) and Stathmin1 ( Supplementary Fig. 6G ). Neither hyperproliferation nor neoplasia was evident in the FT of LPT mice ( Supplementary Fig. S7A ), and the OSE-derived tumors also were PAX8-negative ( Supplementary  Fig. S7B ).
OSE-derived organoids also give rise to ovarian cancer
We were unable to culture OSE organoids in the FTE medium. However, with additional factors, such as hydrocortisone, estrogen, LIF and forskolin, organoids could be propagated from single OSE cells ( Fig. 5A ). These organoids expressed epithelial markers, such as E-cadherin, but unlike FTE organoids, they did not express PAX8 ( Fig. 5B ). As noted above, Lgr5+ cells can repopulate the entire OSE, suggesting that they have stem/progenitor activity. Consistent with this notion, GFP hi (Lgr5-expressing) cells accounted for almost all organoid-forming capability, compared with GFP neg (Lgr5-negative) cells (P<0.001, Fig. 5C ). We next generated OSE organoids from wild type, LP, LT and LPT mice, and added 4-OHT to the medium for 48h to activate CRE. Following 4-OHT treatment, T121 was expressed in LT and LPT organoids, as expected ( Fig. 5D ). Organoid size was not affected, but mutant organoids were more condensed, containing larger numbers of cells ( Fig. 5E ). Although organoidforming capacity was similar among the 4 groups, LPT (P<0.001), and to a much lower extent (P<0.01), LT organoids grew faster ( Fig. 5G ). Finally, we implanted all four types of organoids into the MFP and orthotopically ( Fig. 5H ). Consistent with the cognate GEMMs ( Fig.4F ), only LPT organoids induced metastasize tumors, and organoids and the tumors they evoked had similar histology and marker expression ( Fig. 5I and J).
Transcriptome analysis reveals similarities and differences between FTE-and OSE-derived HGSOC
To molecularly characterize our HGSOC mouse models in an unbiased manner, we performed RNAseq on Supplementary Table S1A ). Furthermore, supervised analysis revealed that the top 50 and top 100 differentially expressed genes between FTE-derived and OSE-derived tumors largely reflected differential gene expression in N-FT and N-O, although other (non-lineage) genes contribute to the top 1,000 DEGs ( Supplementary  Fig. S8 ). Comparing N-FTE and N-O, Pax8 (logFC=4.05, P adj =5.5X10 -14 ), Ltf (logFC=-5.92, P adj <1X10 -15 ), Slc34a2 (logFC=4.84, P adj <1X10 -15 ), which are known FT-specific genes (53) , are highly expressed both in N-FT and T-FT, compared with N-O and T-O. By contrast, the known OSE-specific gene Lgr5 (logFC=5.54, P adj =0) was expressed at significantly higher levels in N-O and T-O than N-FT and T-FT, as were Nr5a1 (encoding a transcriptional activator involved in sex determination and differentiation of steroidogenic tissues, logFC=6.5, P adj <1X10 -15 ), Gata4 (encoding a zinc finger TF), Lhx9 (encoding a target of GATA4, logFC=6.58, P adj <1X10 -15 ), and Unc45b (encoding a GATA4 chaperone, logFC=6.6, P adj <1X10 -15 ); see Supplementary Fig. S8 and Supplementary Table 1B ).
Next we searched for common DEGs in each sample type. Nearly 7,000 (6844) DEGs were seen in OSEderived tumors compared with normal OSE, whereas 5305 DEGs were yielded in T-FT vs N-FT (all at the P<0.05 level). Of these, 1844 genes were shared between T-FT and T-O, compared with the cognate normal samples ( Supplementary Fig. S8 and Supplementary Table S1C ). KEGG analysis showed that DEGs in normal FTE, compared with normal OSE, were enriched for different pathways; e.g., peroxisome-related transcripts were enriched in the FTE, whereas ribosome-related genes, were enriched in the OSE. Although a substantial fraction of differential gene expression in T-FT vs T-O reflected lineage-specific gene expressions, tumors also shared multiple DEGs (compared with their cognate normal cells-of-origin). These were enriched for genes involved in pathways annotated as controlling the cell cycle, DNA replication and DNA repair ( Fig.6C ). Of note, the "p53 signaling pathway" was more enriched in the FTE-derived tumors, whereas homologous recombination, mismatch repair and nucleotide excision repair were more enriched in OSE-derived tumors (Fig. 6C ). Similar to the KEGG analysis, the most enriched GO categories in all of the tumor sets involved cell/nuclear division and cell cycle control and DNA replication and repair, while none of the pathways enriched in the normal FT and normal OSE ( Supplementary Fig.  S9A ). GSEA showed a predominance of G2/M checkpoint control and E2F target genes in all of the tumor samples ( Fig. 6D and Supplementary Fig. S9B ), the latter consistent with dysregulation of RB family/E2F regulation.
To assess the potential relevance of these mouse model findings with human genomic data, we compared protein-coding genes with known human orthologs (17, 598 genes) in each group (T-FT, T-O, N-FT, N-O), and selected genes that were uniquely expressed in each to generate group signatures ( Supplementary Table S2 ). Comparison of the mean of scaled expression of the top 50, 100, 250 or 500 T-FT and T-O genes, respectively, with the other four groups showed the expected segregation of samples ( Supplementary Fig. S10 ). We then applied the mouse T-FT and T-O scores (calculated for either the top 50, 100, 250 or 500 DEGs) to TCGA ovarian cancer data. This analysis revealed that human tumors classified as mesenchymal (mean enrichment score=0.27, 0.26 and 0.25 with gene cutoff at Top 100, 250 and 500, respectively. P<0.001 in all cutoffs when compared to other subtypes), and to a lesser extent, as immunoreactive, were more similar to the mouse T-FT, than to the mouse T-O, signature. By contrast, a larger proportion of proliferative type human tumors more closely resembled the mouse T-O signature (mean enrichment score=0.13, 0.16 and 0.15, respectively. P<0.05 in all cutoffs when compared to other subtypes), whereas differentiated tumors segregated fairly equally into those more similar to FTE-derived (mean enrichment score=-0.05, -0.04 and -0.07 with gene cutoff at Top100, 250 and 500, respectively) vs. OSE-derived mouse tumors (mean enrichment score=-0.1, -0.13 and -0.12 with gene cutoff at Top 100, 250 and 500, respectively), respectively ( Fig. 6E and Supplementary Table S3 ). The robustness of the outcome independent of the number of T-FT and T-O genes chosen gives us confidence in the reliability of this analysis. Furthermore, similar results were obtained by analyzing a distinct set of tumor transcriptomes [(22), data not shown)].
The cell-of-origin can affect response to chemotherapeutic agents
To ask if the cell-of-origin of HGSOC might affect therapeutic response, we tested the response of FTEand OSE-derived tumorigenic organoids to commonly used ovarian cancer drugs. PTPT (FTE) and LPT (OSE) organoids at day 4 of culture (> 3 passages post-Dox and 4-OHT treatment) were released from Matrigel, ~ 150 organoids were re-seeded in each well of 96-well plates pre-coated with Matrigel, and morphology and viability were assessed 5 days later. Tumorigenic FTE and OSE organoids responded similarly to niriparib, olaparib and gemcitabine ( Fig. 7A-C) . By contrast, FTE-derived (PTPT) organoids were significantly more sensitive that OSE (LPT) organoids to carboplatin (P<0.05 at 10 M) and, even more prominently, to paclitaxel (P<0.001 at 5 M, 10 M and 25 M ) treatment ( Fig. 7D and E) . These data indicate that the cell-of-origin could influence response to at least some types of chemotherapy.
DISCUSSION
HGSOC is usually diagnosed late, as bulky multifocal disease that has metastasized widely to the peritoneal cavity, a presentation that makes identifying the cell-of-origin difficult (54) . Although precursor lesions on the FT fimbriae have been reported in up to 60% of HGSOC cases (13) (14) (15) , some studies are more consistent with an ovarian or peritoneal origin (5) (6) (7) . Previous mouse modeling studies showed clearly that FTE can act as the cell-oforigin of HGSOC, but a similar role for OSE has not been excluded. Here, by introducing the same genetic abnormalities into FTE or OSE in GEMMs and organoid models, we have found that HGSOC can originate from either cell type ( Supplementary Fig. S11 ). Importantly, FTE-and OSE-derived tumors differ in their metastatic behavior, transcriptomes and chemosensitivity.
Similar to a previous report, in which combined deletion of Tp53, Brca1/2, and Pten was driven by Pax8rtTA;TetOCre (37), PTPT mice rapidly developed STIC-like lesions and early (<2 month) metastasis to the ovarian surface. Lineage tracing confirmed that Pax8 rtTA is expressed in FTE secretory cells, but importantly, consistent with a recent study (43) , we find that Pax8-ciliated cells also derive from Pax8+ progenitors ( Supplementary Fig. 2 ). Thus, while it is clear that HGSOC can arise from mouse FTE, we cannot be certain that FTE secretory cells (as opposed to Pax8-derived, but Pax8-ciliated cells or a specialized Pax8+ progenitor) are the actual/unique cell-of-origin in the FT. Others have found that the Ovgp1 promoter also can drive HGSOC (38, 39) . This Cre line purportedly is secretory cell-specific (55) , but lineage tracing studies have not been reported. In any event, there should now be little debate that a majority of HGSOC originates from FTE.
Unlike earlier studies using Pax8rtTA;TetOCre to drive combined Brca1/2;Pten;Tp53 deletion, which gave rise to STIC, invasive HGSOC, and eventually, peritoneal carcinomatosis, PTPT mice died prematurely from massive thymic hyperplasia. Subsequent analysis revealed unexpected, leaky expression of the TetOCre promoter in thymic epithelial cells. Previous work showed that E2F activation, resulting from RB family inactivation, leads to increased Foxn1 expression, which drives thymic epithelial cell proliferation (44) . Presumably, Brca1/2;Pten;Tp53 deletion does not cause such hyperproliferation, although conceivably, these defects could affect other thymic epithelial cell properties and, indirectly, immune function, in such mice. Regardless, our results argue for caution in using the TetOCre line to study FTE biology and oncogenesis.
Although HGSOC usually arises from FTE, whether OSE can also give rise to HGSOC had been less clear. Studies in which oncogenic defects were induced by Ad-Cre injections into the ovarian bursa were interpreted as indicating an OSE cell-of-origin (56, 57) , although others have argued that such injections can result in infection of adjacent tissue, including the oviduct or even the uterus (58) . Indeed, our lineage tracing experiments show clearly that bursal injection can target FTE as well as OSE. Nevertheless, several lines of evidence prove that mouse OSE can serve as the cell-of-origin for HGSOC, at least HGSOC induced by combined Tp53 mutation/inactivation and RB family inactivation. First, Ad-Cre-injected Tp53 R172H/fl ;T121 mutant mice develop frank ovarian carcinoma even after salpingectomy. Moreover, Lgr5-Cre, which we confirm by lineage tracing marks OSE, but not FTE, in adult mice, also can drive HGSOC generation by combined RB family inactivation/Tp53 mutation/hemizygosity. Furthermore, OSE organoids in which the above genetic defects are induced in vitro, give rise to HGSOC-like lesions.
Although metastasis could not be evaluated in PTPT mice, organoid transplantation clearly shows that mouse FTE-derived HGSOC metastasizes widely. By establishing conditions for OSE-derived organoids, we could directly compare tumorigenesis by FTE-and OSE-derived HGSOC. Interestingly, these experiments suggest that the cell-of-origin can influence HGSOC behavior: FTE-derived tumors showed greater ability to disseminate, whereas OSE-derived HGSOC more commonly formed large, solitary lesions that show less frequent (although nonetheless significant) dissemination. Notably, human HGSOC also differs in its pattern of growth and metastasis, with some cases forming large primary tumors and fewer, less diffuse tumor deposits, whereas others show peritoneal carcinomatosis (59) . Defined combinations of genetic defects (e.g., as found in TCGA) can be engineered into our FTE and OSE organoids, allowing various aspects of the transformation process (proliferation, polarity, apoptosis, necrosis, invasion) to be deconstructed in vitro and tumorgenicity to be assessed in vivo. It will be interesting to determine the extent to which the differential behavior observed here reflects the particular combination of cell-of-origin/oncogenic defects vs. effects of the cell-of-origin per se. Our RNAseq data, however, suggest that whereas common pathways and processes are de-regulated by imposing the same oncogenic insults on FTE and OSE, there are marked differences in which specific genes within these pathways/process are affected in the two cell types. Such differences might manifest as differential sensitivities to the two agents used as front line therapy for HGSOC, carboplatin and paclitaxel. In this regard, it is interesting to note that whereas repair genes are differentially expressed in both FTE-and OSE-derived tumors (compared with their cognate normal tissues), the extent of altered expression is greater in the latter. By contrast, signaling from p53-dependent pathways (presumably by alternative mechanisms, given the combined TP53 mutation/deletion in both types of tumors) is elevated to a greater extent in FTE-derived, than in OSE-derived tumors. Either or both of these differences might help explain the observed cell-of-origin-dependent differences in chemosensitivities.
Several lines of evidence suggest that our results are relevant for human HGSOC. First, a recent case report documented the development of stage IV HGSOC three years post-salpingectomy without evident STIC in the excised FT (60) . Furthermore, recent exome sequencing (24), transcriptome (22) and ChiPseq experiments (23) support the notion that HGSOC can arise at sites other than the FTE. Our comparison of the transcriptome of FTEand OSE-derived HGSOC, respectively, compared with TCGA samples, indicates greater resemblance of some human HGSOCs, particularly proliferative type HGSOC, to OSE-derived tumors. Understanding the contribution of the cell-of-origin to HGSOC generation could be of substantial importance, given that our results indicate that tumorigenic OSE-and FTE-derived organoids bearing the same oncogenic defects have different biologic behavior, including sensitivities to anti-neoplastic drugs.
METHODS
Mice
Rosa26 (T121 mice) were described previously (36) . Pax8rtTA and TetOcre strains were described previously (37) . 
Animal experiments
For lineage tracing of Pax8+ FTE cells, Pax8rtTA;TetOcre;Rosa26-LacZ female mice (6-8 week old) were induced with 2mg/ml doxycycline in their drinking water for 2 days. Mice were sacrificed, and their reproductive systems were collected, at 2 or 60 days after Dox administration. Lgr5-Cre;Rosa26-tdTomato mice (6-8 weeks old) were injected intraperitoneally with a single dose of 4-OHT in sesame oil (10 mg/ml) at a concentration of 2 mg (in 200 µl), and then sacrificed at 48h or 4 months after induction. Superovulation was performed by injection with 5 IU pregnant mare serum gonadotropin (PMSG, Sigma) and 5IU of human chorionic gonadotropin (hCG, Sigma), spaced 48 h apart. For Cre induction in PTP, PTT and PTPT mice, Dox (2mg/ml) was added for 2 weeks to the drinking water of 6 week-old females, and relevant tissues were collected for H&E and IHC after 1 month. For Cre induction in LP, LT and LPT mice, 6 week-old females were injected with 4-OHT, and mice were sacrificed at indicated time.
For ovarian bursa injection, recombinant adenovirus Ad5-CMV-Cre (Ad-Cre) was purchased from the Vector Development Lab at Baylor College of Medicine. Superovulation was performed in 6-8 week old female Tp53 R172H/fl ;T121 mice, as described (35) . Approximately 1.5 days later, a single injection of 10 µl Ad-Cre (10 11 -10 12 infectious particles/ml) was delivered into one surgically exposed ovarian bursa, with the contralateral ovary serving as a control. Rosa26-LacZ female mice were used to test Cre expression and were euthanized 2 weeks postinjection. Salpingectomies on Tp53 R172H/fl ;T121 females were performed 3 days after Ad-Cre injection, and mice were euthanized 3 months afterwards. Animals were routinely monitored for signs of distress, poor body condition, and tumor burden, and were euthanized according to veterinary recommendations. For survival experiments, the mice were monitored until their death or upon veterinary recommendation.
Organoids were amplified in 6-well plates coated with 200 µl of Matrigel/well and supplemented with 2 ml organoid growth medium. Orthotopic injections were performed on 8 week-old female mice. For surgeries, mice were anesthetized by intraperitoneal injection of 0.2 ml xylazine hydrochloride, shaved, and cleaned with betadine. A midline dorsal incision was made, followed by an incision into the peritoneal cavity above the fat pad of the right ovary. The ovary was externalized through the incision and 0.5 X 10 6 cells/matrix mixture (1:1, 15-20 µl) was injected by inserting a 27G needle into the fat pad. Only one ovary in each animal was injected, with the contralateral ovary serving as a control. The injected tissue was returned to the peritoneal cavity, the inner incision was sutured, and the outer incision was sealed with wound clips. For mammary fat pad injections, cells were resuspended with Matrigel (1:1, around 15 µl) and injected into the mammary fat pad just inferior to the nipple of female mice (6-8 weeks) with 28G needle (BD insulin syringe). Mice that developed tumors were euthanized at the indicated times, when tumors ulcerated or reached a maximum diameter of 20 mm, or when mice showed any sign of discomfort due to tumor burden.
Organoid Cultures and Assays
For FTE organoids, FT fimbriae from wild type, PTP, PTT and PTPT were dissected under a microscope, minced and digested with Collagenase type I and dispase 0.012% (w/v) (STEMCELL Technologies) at 37℃ for 1 hour, followed by incubation in TrypLE™ Express Enzyme (Thermo Fisher Scientific) for 10 min at 37℃, and inactivation with FBS (Gibco) 1% in DMEM media (Gibco). Dispersed FTE cells were passed through a strainer (70 µm), mixed with Matrigel (BD Bioscience), seeded and cultured as described (61) . After Matrigel solidified (10 min at 37℃ incubator), culture medium was added. The medium was based on Ad+++ medium (AdDMEM/F12 (Invitrogen) with HEPES (Thermo Fisher Scientific), penicillin/streptomycin (Life Technologies), Glutamax (Life Technologies)), supplemented with B27 (Invitrogen), N2 supplement (Thermo Fisher Scientific), 1.25 mM Nacetylcysteine (Sigma), 50 ng/ml EGF (Thermo Fisher Scientific), 500 ng/ml RSPO1 (Peprotech) or R-spondin-1conditioned medium (25%, v/v), and 100 ng/ml Noggin (Peprotech). For the first 3 days after thawing, culture medium was supplemented with 10 mM Y-27632 (Sigma-Aldrich). For OSE organoid culture, fat and adjacent fallopian tubes were carefully removed under a microscope, and the ovaries were digested with 0.25% trypsin/EDTA (Invitrogen) and inactivated with DMEM media containing 1% FBS (Gibco) at 37℃ for 30 min. Supernatants, containing cells stripped from the OSE, were seeded in Matrigel, and cultured in Ad+++ medium, supplemented with B27, N-acetylcysteine (1 mM, Sigma), WNT3a-conditioned medium (50% v/v), R-spondin-1conditioned medium (10% v/v), Noggin (100 ng/ml, Peprotech), EGF (0.0125 µg/ml), nicotinamide (10 mM, Sigma), A83-01 (0.5 µM, Tocris Bioscience), hydrocortisone (0.5 µg/ml, Sigma), and β-estradiol (100 nM, Sigma). Passaging and freezing were carried out as described above for FTE organoids. WNT3a-and R-spondin-1conditioned media were prepared as described (62) .
Organoid medium was changed every 2-3 days, and they were passaged approximately 1:4 (10,000 cells/well) every 6-8 days. For passage, growth medium was removed, and the Matrigel was resuspended in cold Cultrex® Organoid Harvesting Solution and transferred to a 15-ml Falcon tube, which was placed on ice for 15 minutes. Organoids were recovered by centrifugation at 1,000 g for 5 minutes and resuspended in 500 µl TrypLE Express Enzyme (Gibco) for 10 minutes at 37℃. Cells were then seeded as indicated for each experiment. For freezing, cells were resuspended in organoid medium with 10% DMSO and 10% FBS, cooled, and stored in liquid nitrogen.
To activate Cre in vitro, 0.5 µl of Dox (1 mg/ml) were added to 500µl of freshly isolated PTP, PTT and PTPT cells, which were plated as described above. Similarly, 1 µg/ml 4-OHT was used to activate CRE in LP, LT and LPT organoids. All data were generated at least 3 passages after induction. Organoid size was quantified as the surface area of horizontal cross sections. If all organoids in a well could not be measured, several random, nonoverlapping pictures were acquired from each well using an Invitrogen™ EVOS™ FL Digital Inverted Fluorescence Microscope, and analyzed by using ImageJ software. Organoid perimeters for area measurements were defined manually and by automated determination using the "Analyze Particle" function of ImageJ, with investigator verification of the automated determinations. Organoids touching the edges of images were excluded from counting.
To compare organoid-forming efficiency of different genotypes, 5,000 cells were seeded into a 24-well plate, total organoid number was counted under a light microscope after 5-7 days in culture, and the percentage of organoids formed relative to organoids formed by wild type cells was calculated.
For in vitro growth curves, organoids were incubated in TrypLE Express (Gibco) for 15 min at 37℃, followed by an additional 5 min digestion in Dispase I. Isolated cells were passed through a strainer, seeded at 2 x10 4 cells/well in a 24 well plate and placed in culture medium. At the indicated times, cells were recovered as described above, and viable counts were obtained by trypan blue exclusion.
Drugs were tested in organoids based on a previously described protocol (62) . Briefly, organoids in culture at day 4 were released from Matrigel and diluted to 50 organoids/µl in growth medium lacking N-acetylcysteine and Y-27632. Clear bottom 96-well plates were coated with 20 µl Matrigel before the addition of 30 µl of organoid suspension. The indicated concentrations of paclitaxel (Selleck Chem), carboplatin (Sigma), olaparib (Selleck Chem), niraparib (Selleck Chem), or DMSO (control) were added in triplicate. On day 5 of treatment, media were removed and the Matrigel drops were suspended in 40 µl CellTiter-Glo 3D (Promega) and 80 µl advanced AdDMEM/F12, incubated for 30 min at room temperature before luminescence was measured in FlexStation® 3 Multi-Mode Microplate Reader. Results were normalized to DMSO controls.
Invasion was assessed by using chambers with 8 µm pore size polycarbonate membrane (Transwell) inserts (Costar). Matrigel (30 µl) was added to the chambers and allowed to solifiy at 37 for 10 minutes. Wild type, PTP, PTT, or PTPT cells (2 x 10 4 /50µl Ad+++ medium/well) were seeded into the Matrigel-coated top chamber, and allowed to attach for 12 hours, followed by the addition of 500 µl of culture medium to each well. After an additional 96 hours of incubation, the upper surface of the Transwell membrane was scrubbed carefully several times with a cotton swab soaked in PBS to remove non-invaded cells. The lower membrane was then rinsed with PBS carefully several times, and cells that had invaded were visualized by staining with crystal violet and counted under a microscope. Invasion was calculated as the average number of cells per 10x field, determined by Image J software.
FACS
Ovaries from Lgr5-Cre (Lgr5-EGFP-ires-Cre ERT2 ) females (6-8 weeks) were digested as described above and recovered OSE cells were passed through a strainer (40 µm) to obtain single-cell suspensions. OSE cells were pelleted by centrifugation at 1,000 g for 5 min and resuspended in PBS containing 2% FBS, Rock inhibitor (Y-27632, 10 µM, STEMCELL Technologies Inc.), DAPI (1µg/ml), FACS was performed immediate by using a MoFlo TM XDP, and sorted GFP hi and GFP neg cells were seeded at 5000/well. Organoids were counted 6 days later, and organoid forming efficiency was calculated as number of the organoids/number of cells seeded, pooled from three biological replicates.
Histology and Immunostaining
Tissues were fixed in 4% paraformaldehyde (PFA) in PBS at 4℃ for 4 hours. Organoids were fixed in 4% PFA for 15 minutes and placed in Histogel (Thermo Fisher Scientific) before tissue processing and embedding. Formalin-fixed paraffin-embedded (FFPE) tissue sections (5 µm) were de-paraffinized, rehydrated, and then stained with hematoxylin and eosin (H&E) or subjected to IHC. For antigen retrieval, slides were autoclaved in 0.01 M citrate buffer (pH 6.0). Endogenous peroxidase activity was quenched in 3% H 2 O 2 in methanol for 15 min and sections were blocked with 0.5% BSA-PBS for 1h. Primary antibodies were added overnight at 4℃, then washed with PBS 3x10 min, incubated with HRP-labeled secondary antibodies, and after washing with PBS 3x for 10 minutes each, signals were visualized by using the HRP Polymer Detection Immunofluorescence was performed in frozen tissue sections (5 µm) or in whole organoids released by gently dissolving the Matrigel in ice-cold PBS. Following fixation as above, cells were permeabilized in PBS containing 0.5% Triton X-100 and blocked in PBS containing 1% BSA, 3% normal goat serum and 0.2% Triton X-100. Primary antibodies were incubated at 4℃ overnight, and sections were washed in PBS 3x for 10 minutes each, followed by incubation with DAPI (2 µg/ml) and Alexa 488-, 555-or 647-conjugated anti-chicken, anti-rabbit or anti-mouse antibodies, as indicated. After washing, samples were mounted with ProLong Gold antifade reagent (Life Technology). Primary antibodies were: GFP 1:300 (ab13970, Abcam), 
Laser capture microdissection and RNA extraction
Tissues, including normal ovary and fallopian tube (fimbriae), ovarian tumors from LPT females, and STICs from PTPT mice, were embedded in FSC 22 Clear Frozen Section Compound and immediately frozen with liquid N 2 . The resultant blocks were cut at 5-8 µm and mounted on a PEN membrane frame (Leica), followed by air-drying the slides for 30 minutes at room temperature. Laser capture was performed with a Leica LMD6000 laser microdissection system, and excised pieces were harvested into 200 µl RNase-free tubes, which were carefully recovered from the microscope, centrifuged, and placed on ice. RNA was extracted by using the miRNeasy mini Kit (Qiagen), following the manufacturer's instruction.
RNA-Sequencing and Analysis
Libraries were prepared using the Illumina TruSeq Stranded Total RNA Sample Preparation Kit. and sequenced on an Illumina HiSeq 4000 sequencer using 150bp paired-end reads by the Perlmutter Cancer Center Genome Technology Center shared resource (GTC). Sequencing results were demultiplexed and converted to FASTQ format using Illumina bcl2fastq software. The average number of read pairs was 60.3M per sample. Data were processed by the Perlmutter Cancer Center Applied Bioinformatics Laboratory shared resource (ABL). The reads were adapter and quality trimmed with Trimmomatic [http://www.ncbi.nlm.nih.gov/pubmed/24695404] and then aligned to the mouse genome (build mm10/GRCm38) using the splice-aware STAR aligner [http://www.ncbi.nlm.nih.gov/pubmed/23104886].
The featureCounts program [https://www.ncbi.nlm.nih.gov/pubmed/24227677] was utilized to generate counts for each gene based on how many aligned reads overlap its exons. These counts were then normalized and used to test for differential expression using negative binomial generalized linear models implemented by the DESeq2 R package FT/O-specific gene signatures were determined by calculating differentially upregulated genes pair-wise between all four examined groups. For each group, they were ranked by the highest p-value across all three comparisons for each gene. The genes were subset to protein coding and with available human ortholog predictions in any of the 14 databases indexed by the HUGO Gene Nomenclature Committee Comparison of Orthology Predictions resource. To measure the FT/O enrichment in individual samples, the normalized counts were scaled and centered, and the mean was calculated for all genes comprising the signature. TCGA Ovarian Cancer batch effects normalized mRNA data and molecular subtypes were retrieved from the UCSC Xena Pan-Cancer Atlas hub.
Quantification and statistical analysis
Unless otherwise specified, data are presented as mean ± SEM. Survival rates were analyzed by log-rank test, using GraphPad Prism software. P values were determined by two-tailed Student's t-test, unless otherwise specified, with P< 0.05 considered statistically significant. 
